IP Library › Granted Patent US 12685787
Granted Patent B2
US 12685787 · App. 19/431,261 · Granted Jul 21, 2026

Lipid nanoparticles with RNA for cosmetic treatment

Inventors: Frank Ho Pak Lau (River Ridge, LA); Jason Bourgeois (San Antonio, TX)
Assignee: Lipovectra Inc.
A61K48/0058A61K38/17A61K48/0041
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685787
App. No.
19/431,261
Filed
Dec 23, 2025
Granted
Jul 21, 2026
Kind
B2
Art Unit
1636
USPC
514/44R
Abstract

A method for directing a change in cell state of white adipose tissue (WAT) which involve treating WAT cells with mRNA encapsulated inside lipid nanoparticles (LNPs). The mRNA encodes UCP1 or other proteins that may transition WAT to brown adipose tissue (BAT). The LNP may contain (C14-4:NCL:Cholesterol:PEG/Lipid Conjugate) at the molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

Claims (21)

1 . A pharmaceutical composition comprising:

a synthetic mRNA comprising the nucleotide sequence set forth in SEQ ID NO: 6;

wherein the synthetic mRNA is packaged in a lipid nanoparticle (LNP).

2 . The pharmaceutical composition of claim 1 , wherein the LNP comprises (C14-4: non-cationic lipids (NCL): Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

3 . The pharmaceutical composition of claim 1 , wherein the LNP comprises (SM-102:NCL:Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (50:10:38.5:1.5), (48.3:9.1:40.5:2.1) or (46.6:10.4:41.2:1.8).

4 . The pharmaceutical composition of claim 1 , wherein all uridine nucleotides of the synthetic mRNA are substituted with pseudouridines.

5 . The pharmaceutical composition of claim 1 , wherein all uridine nucleotides of the synthetic mRNA are substituted with N1-Methylpseudouridines.

6 . A pharmaceutical composition comprising:

a synthetic mRNA comprising the nucleotide sequence set forth in SEQ ID NO: 3;

wherein the synthetic mRNA is packaged in a lipid nanoparticle (LNP).

7 . The pharmaceutical composition of claim 6 , wherein the LNP comprises (C14-4: non-cationic lipids (NCL): Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

8 . The pharmaceutical composition of claim 6 , wherein the LNP comprises (SM-102:NCL:Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (50:10:38.5:1.5), (48.3:9.1:40.5:2.1) or (46.6:10.4:41.2:1.8).

9 . The pharmaceutical composition of claim 6 , wherein all uridine nucleotides of the synthetic mRNA are substituted with pseudouridines.

10 . The pharmaceutical composition of claim 6 , wherein all uridine nucleotides of the synthetic mRNA are substituted with N1-Methylpseudouridines.

11 . A pharmaceutical composition comprising:

a synthetic mRNA comprising the nucleotide sequence set forth in SEQ ID NO: 4;

wherein the synthetic mRNA is packaged in a lipid nanoparticle (LNP).

12 . The pharmaceutical composition of claim 11 , wherein the LNP comprises (C14-4: non-cationic lipids (NCL): Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (35:16:46.5:2.5), (50:10:38.5:1.5) or (56.5:10:31.8:1.7).

13 . The pharmaceutical composition of claim 11 , wherein the LNP comprises (SM-102:NCL:Cholesterol:PEG/Lipid Conjugate) at a molar ratio of (50:10:38.5:1.5), (48.3:9.1:40.5:2.1) or (46.6:10.4:41.2:1.8).

14 . The pharmaceutical composition of claim 11 , wherein all uridine nucleotides of the synthetic mRNA are substituted with pseudouridines.

15 . The pharmaceutical composition of claim 11 , wherein all uridine nucleotides of the synthetic mRNA are substituted with N1-Methylpseudouridines.